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Theshortageofappropriatedonororgansandtheexpanding poolofpatientswaitingforheart transplantationhaveledto growing
interest in alternative strategies, particularly in mechanical circulatory support. Improved results and the increased applicability
anddurabilitywith left ventricular assistdevices (LVADs)haveenhancedthis treatment option availableforend-stageheart failure
patients. Moreover, outcome with newer pumps have evolved to destination therapy for such patients. Currently, results using
nonpulsatile continuous ﬂow pumps document the evolution in outcomes following destination therapy achieved subsequent to
the landmark Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure Trial (REMATCH),
aswellastheoutcomeofpulsatiledesignedsecond-generationLVADs.Thisreviewdescribes thecurrently availabletypes ofLVADs,
their clinical use and outcomes, and focuses on the patient selection process.
1.Introduction
Hearttransplantationisstillthetherapyofchoiceforpatients
with sustained heart failure resistant to any medical therapy.
More than 16 million people are currently diagnosed with
chronic heart failure (CHF) in Europe and the United States,
where its prevalence averages 2.5% of the normal population
[1, 2]. CHF increases signiﬁcantly after age 65, and the
populationin thisgroupwill doublewithin thenext 20years,
suggesting heart failure incidence will similarly [3].
In the last decades, long waiting times for cardiac
transplantation and subsequent increased mortality have
led to an increase in the use of left ventricular assist
devices (LVADs). Permanent mechanical circulatory support
by new, smaller devices is a promising therapeutic option
developed to provide an alternative to transplantation and
to reduce mortality on the heart waiting list. The primary
focus in this ﬁeld was to develop a total artiﬁcial heart
(TAH), but this has had limited success and, as a result,
shifted attention to ventricular assist devices. The ﬁrst-
generation of implantable ventricular assist devices (VADs)
were pulsatile, volume-displacement pumps. The start of
the modern LVAD era began with the introduction of the
HeartMate XVE in1998. Althoughthe XVE launched amidst
great fanfare and high expectations, the device failed to
displace the long-standing view that mechanical ventricular
support was merely an expensive gimmick. These devices
provide excellent circulatory support and improve survival
until heart transplantation. However, they have many appli-
cation limitations, such as a large volume, the excessive
surgical dissection required for placement of the device,
presence of a large diameter driveline, noisy pump opera-
tion, and particularly limited mechanical durability. Other
complications are bleeding, infections and thromboembolic
events. During the succeeding decade, vast improvements
in pump design resulted in a new crop of LVADs, whose
attributes are transforming LVAD therapy into a kind of
standard of care for end-stage heart failure [4–17]. LVAD
therapy has now evolved into a solution which is strikingly
superior to optimal medical therapy [4–6, 11].
The one factor most responsible for the advancement
of LVAD therapy into the standard of care is the dramatic
improvement in clinical outcomes seen in recent years [4,
12, 17]. Smaller nonpulsatile continuous-ﬂow blood pumps
(second- and third-generation LVADs) became available.
Because of their simpler design (no mechanical bearings,
no mechanical or biological valves), these devices showed a
potentially longer durability [9, 12–14, 18–22].
This paper describes the currently available types of
LVADs,theirclinicaluseandoutcomes,patientselection,and
further directions on this growing ﬁeld.2 Cardiology Research and Practice
2.LeftVentricularAssist Devicein
Practiseand Outcome
2.1. First Generation of LVAD Types. The most common and
routinely used pulsatile devices are paracorporeal pumps
such as Thoratec’s paracorporeal ventricular assist devices
(Figure 1, PVAD; Thoratec Inc.; Pleasanton, Calif, US) and
the Berlin Heart Excor (Berlin Heart AG, Berlin, Germany),
and implantable pumps such as HeartMate XVE (Figure 1,
Thoratec Inc.), or Novacor (World Heart Corp., Oakland,
Calif).
The HeartMate LVAD was ﬁrst used in a clinical trial
starting in 1986 as a pneumaticly actuated system that
required a large cumbersome console that did not allow
patients much mobility outside the hospital. This system
proved to be eﬀective as a long-term support device with
the end goal of heart transplantation [23]. The HeartMate
System underwent years of development and, in 1991, a
clinical trial of a vented electric (VE) model was begun.
This electric system allowed a greater amount of mobility
with portable battery units carried in a holster [24]. Since
then, both models have shown a 60% to 70% rate of survival
to transplantation. The worldwide average implant duration
is 80 to 100 days, and maximum duration on support has
exceeded 2 years. The probability of device failure has been
shown to be 35% at 2 years.
The HeartMate XVE (Thoratec Corp. Pleasanton, Calif),
a pulsatile pump, can be operated in either a ﬁxed-rate
(partial support) or automatic mode (full support), and it
can produce a maximum stroke volume of 83ml at varying
rates (from 50 to 120beats/min), resulting in ﬂow rates
from 4 to 10l/min (Figure 1). The pulsatile ﬂow is created
using a pusher plate system [25]. In automatic mode, the
pump senses when the chamber is full and activates the
pusher plate. In case of an emergency, a portable hand
pump can be used to activate the device. The patient’s body
size is an important factor in allowing device placement.
The size of the device requires patients to have a body
surface area of more than 1.5m2. The device is made of
a titanium alloy external housing with inﬂow and outﬂow
tracts that utilize porcine xenograft valves (25mm). The
unique characteristic of the device is its internal blood-
contacting surface, which is made on one side of textured
titaniumandontheotheroftexturedpolyurethane.Thistex-
tured surface encourages the deposition of a ﬁbrin-cellular
matrix that forms a pseudoneointima. The formation of this
surface greatly reduces the need for anticoagulation because
thrombus formation is greatly reduced [26]. Patients with
thesedevicestakeaspirin(primarilyasananti-inﬂammatory,
not as an anticoagulant) as their only anticoagulation with
a subsequent low rate of thromboembolic complications
(7%) [11, 25–27]. The HeartMate VE was used in the
Randomized Evaluation of Mechanical Assistance for the
Treatment of Congestive Heart Failure (REMATCH) trial
to compare medical and circulatory assist device treatments
for end-stage heart failure. Patients with this device showed
better results than the medically treated group. However, the
survival in the VAD group after 2 years was 28%, compared
to only 8% in the medically treated patients [11]. This trial
established the substantial risk of mechanical failure and
device-related complications inherent in the ﬁrst-generation
pulsatile devices [11, 28].
2.2. Second Generation of LVAD Types. The engineering
of continuous-ﬂow rotary pump technology represents a
milestone and novel design concept for LVADs. These
devices have now largely replaced the use of the ﬁrst-
generation of pulsatile, volume displacement pumps. The
second-generation rotary pumps have the advantage of a
smaller design and potential for greater long-term mechan-
ical reliability by eliminating the reservoir chamber and
valves needed for ﬁrst-generation pulsatile pumps [10]. The
second-generation rotary blood pumps are typically with an
“axial” blood ﬂow path, which have an internal rotor within
the blood ﬂow path that is suspended by contact bearings.
In comparison, third-generation pumps have generally been
used to categorize continuous-ﬂow rotary devices with an
impeller or rotor suspended in the blood ﬂow path using a
“noncontact” bearing design.
The most common implantable pumps are the Heart-
Mate II (Thoratec Corp, Pleasanton, CA, USA), and the
Jarvik 2000 (Jarvik Heart Inc.) [16, 17, 22, 29]. Up to date,
the HeartMate II is the most successful second-generation
pump worldwide and approved as bridge to transplant and
as destination therapy [4–7].
The HeartMate II LVAD is an axial ﬂow pump that
had its origin in the early 1990s (Figure 2)[ 30]. This is
an axial-ﬂow rotary LVAD made of titanium with a pump
implant volume of 63ml. The HeartMate II contains a rotor
capable of producing ﬂow rates greater than 10L/min at
resolutions (RPM) ranging from 8,000 to 15,000 (Figure 2)
[10]. The inﬂow cannula is connected to the apex of the left
ventricle, with the outﬂow graft connected to the ascending
aorta. Like the other axial-ﬂow pumps, there is a risk of
generating negative intraventricular pressure and collapsing
theventricle.Asaresult,inﬂow cannulapositioning andven-
tricular preload are important. The intraventricular portion
of the inﬂow tract has been elongated and as a result, tends
to stent open the middle of the ventricle, thus improving
reliability of continuous ﬂow throughout the cardiac cycle
[30]. Anticoagulation is at present recommended to keep
INR between 1.5 and 2.5 [31]. The pump is inserted
preperitoneally or within the abdominal musculature. Power
and control are supplied through a percutaneous lead that is
attachedtoacontrollerthatcanbeconnectedtorechargeable
batterieswornbythepatientortoanexternalpowermodule.
The system is operated at a ﬁxed rotational speed set by the
clinician [30].
2.3. Third Generation of LVAD Types. Levitation systems
utilized in third-generation rotary blood pumps suspend
the moving impeller within the blood ﬁeld without any
mechanical contact. The magnetic and/or hydrodynamic
levitation of the impeller without any contact bearings
with the pump is the major advancement of the third-
generation pumps. These designs have the potential to sig-
niﬁcantly improve device durability, but it should be notedCardiology Research and Practice 3
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Figure 1: First generation pulsatile left ventricular assist device HeartMate XVE (a) and Thoratec paracorporeal device (b).
(a) (b)
Figure 2: HeartMate II left ventricular assist device and cross-sectional internal view (Illustration Thoratec Corporation). Reprinted with
permissionfrom Thoratec Corporation.
that blood immersed bearings such as in the HeartMate
II have been reported to have almost imperceptible wear,
and with estimated life well in excess of 15 years [32].
Pump design can be further distinguished by utilization of
hydrodynamic levitation only (VentrAssist; Ventracor Ltd.,
Sydney, Australia), and hydrodynamic levitation working
in synergy with magnetic levitation for suspension (HVAD
Pump, HeartWare, Inc.; Levacor; World Heart Corp.), or full
magnetic suspension such as the HeartMate III, Thoratec
Corp. [10, 18, 33–35]. The Berlin Heart Incor (Berlin Heart
AG) [36] and the DuraHeart (Terumo Somerset, USA) are
both magnetic levitation pumps and also assigned to 3rd
generation pumps [9, 18].
The HVAD Pump, part of the HeartWare Ventricu-
lar Assist System (HeartWare Inc), is a small centrifugal
ﬂow pump with a displacement volume of 50ml and an
output capacity of 10L/min (Figure 3). A unique wide-
blade impeller is suspended by hybrid passive magnets and
hydrodynamic forces. There are no points of mechanical
contact within the pump, eﬀectively ensuring a “wearless”
system. The design integrates two motor stators for single-
motor fault protection to increase reliability. An integrated
inﬂow cannula is inserted into the left ventricle and is
held in position by an adjustable sewing ring; the pump
is positioned in the pericardial space. The 10-mm outﬂow
graft is anastomosed to the ascending aorta. External system
components include the microprocessor-based controller,
a monitor, lithium-ion battery packs, alternating current
and direct current power adapters, and a battery charger.
Physiologic control algorithms are incorporated for safe
operation. Preclinical life cycle tests have shown the HVAD
to be highly reliable. This system design oﬀers reliability,
portability, and ease of use for ambulatory patients [37].
The device size and the integrated inﬂow cannula allow it
to be implanted completely in the pericardial space, directly
adjacent to the heart, thereby avoiding the abdominal
surgery generally required to implant competing devices.
Reduced procedural invasiveness is expected to lead to more4 Cardiology Research and Practice
(a) (b)
Figure 3: External (a) and internal (b) view of third-generation continuous-ﬂow rotary left ventricular assist device HVAD (HeartWare).
Reprinted with permission from HeartWare.
rapidpostoperative recoveryand improved patientoutcomes
[12]. Additionally, the biventricular use has been described
successfully, but is as yet an “oﬀ-label” use [13]. In such a
case,additionalmodiﬁcationslikepulmonaryarterybanding
or crimping of the outﬂow cannula may be necessary to
increase the afterload for the right ventricular assist [13, 38].
2.4. Contemporary Outcomes. A patient with end-stage heart
failure (who is not a transplant candidate) today faces
two contrasting options. The ﬁrst rests with the traditional
approach of optimal medical therapy which would involve:
(1) severe debility resulting in overwhelming fatigue and
precluding any form of physical activity, (2) frequent hos-
pitalizations to treat acute decompensations, and (3) a two-
year survival rate under 15% [1–3, 11]. The second option
involves implantation of an LVAD with a two-year survival
rate last reported to be 70% for implants in 2007 and early
2008 (but likely well above 70% for implants performed
today), as well as substantial improvements in quality of life
as these patients are typically able to return to normal daily
activities [4–10, 12, 14–17].
In support, see Figure 4 for a summary of survival
data for patients enrolled in pivotal US DT trials treated
with Thoratec’s current-generation HeartMate II, prior-
generation HeartMate XVE, and optimal medical therapy
[4, 5, 7, 11].
As shown in Figure 4, 2-year survival with optimal
medical therapy was approximately 8% for patients between
1998 and 2001. Unfortunately, there have been no major
improvements in the care of heart failure patients since
then, suggesting that survival with medical therapy has not
changed appreciably. This factor is further supported by
the observation that there was no diﬀerence in survival for
patientsimplantedwiththeHeartMateXVEfrom1998–2001
when compared with those implanted 2005–2007 [6].
Pulsatile, volume displacement devices have several lim-
itations inherent in their engineering design that preclude
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Figure 4: Two-year survival trends of HeartMate clinical trials.
Sources:ISHLT,Slaughter[4],Rogers[5],Pagani[7],andRose[11].
their practical use for long-term circulatory support. The
most critical constraint of the majority of these devices has
been the incidence of pump malfunctions resulting in death
orneedforreoperations[15].ThelandmarkREMATCHtrial
showed for the HeartMate XVE a 35% failure rate after 2
years, with a mortality of more than 10% [11]. The rate
of serious infection, including the pump itself, the pump
pocket, and the driveline range between 18–80% after LVAD
placement.
For the ﬁrst-generation VADs, the published range of
thromboembolic events reaches from 5 to 50% depending
on the diﬀerent LVAD types and variation in anticoagulation
regimes. The lowest thromboembolic rates have been pub-
lished for the HeartMate XVE (3–9%) [11].
Reports from the second-generation rotary pumps have
demonstrated eﬃcacy in providing hemodynamic support,
favourablerisk tobeneﬁtassessment, andimprovedmechan-
ical performance [4, 7, 10, 16]. Up to date, the HeartMateCardiology Research and Practice 5
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Figure 5: Actuarial survival comparison between HeartMate
studies and HVAD assist device. (1) Results from the US BTT Trial
presented at AHA Meeting in November by Aaronson [14], (2)
Str¨ uber et al.2010 [20], (3) Miller et al.2007 [10], (4) HeartMate II
Post-approvel study [39], (5) Str¨ uber et al. 2008 [21], (6) Pagani et
al. 2009 [7], (7) Slaughter et al. 2009 [4].
II is the most successful second-generation LVAD with over
6000 implants worldwide and 1500 implants in Europe.
The reported survival rates have improved as experienced
was gained from the initial clinical trial results [10]t ot h e
postapproval study [39] from 89% to 96% (30 days), from
75% to 90% (6 months), and from 68% to 85% (1 year)
(Figures 4 and 5).
Additionally, results from clinical studies also have
shown early improvements followed by long-term stability
of renal and hepatic function, as well as limited adverse
eﬀects on neurocognitive performance [6, 10, 17]. These
improvements have led to increased acceptance of LVAD
therapy for long-term support.
At the ISHLT conference in April 2010, Mark Slaughter
from the University of Louisville presented data on 93
patients implanted with the HeartMate II for Destination
Therapy at two centers (University of Louisville and Duke)
from 2005 to 2009. This data showed that patients implanted
during 2007–2009 had a 2-year survival rate of 70%, a sub-
stantial improvement over the 58% survival rate observed in
the HeartMate II’s pivotal trial in destination therapy (DT),
which enrolled patients from 2005–2007. The important
conclusion of this study is survival rates are continuing to
improve as surgeons gain experience in patient selection,
operative techniques, and postop care.
The incidence of thromboembolic eventsis relatively low
for the HeartMate II and ranges from 3 to 6 events per 100
patient-years[4].Intherandomizeddestinationtherapytrial
of the HeartMate II versus the HeartMate XVE, the hemor-
rhagic and ischemic stroke rates (at 0.06 and 0.07 events per
patient-year)tendedtobelowerincomparisontoHeartMate
XVE (at 0.10 and 0.12 events per patient-year) [4]. Other
second-generation devices (DuraHeart, VentrAssist) show
somewhat higher incidence of neurological complications
[9, 40]. The incidence of driveline and pump infection is
still remarkable, ranging from 13 to 27% [6, 10, 17, 21, 28].
Howeverthelowest rateis reportedfortheHeartMateII[19].
In comparison to severe device-related infections with ﬁrst-
generation pumps, those with second-generation devices
seldom lead to fatal outcomes [6, 28].
Of note, while the survival data outlined above only
involves patients implanted with second-generation pumps,
we currently do not expect any major diﬀerences in the 2-
yearsurvival amongany ofthelaterstagedevices.Insupport,
we note that data from HeartWare’s European BTT trial
(third-generation) appears as good as the data from Thor-
atec’s US BTT trial (Figure 5)[ 12]. Additionally, at the 2010
AHA scientiﬁc meeting, initial results from the company’s
U.S. Bridge-to-Transplant clinical trial (ADVANCE) were
presented. This was designed as a noninferiority trial and
the data showed survival to transplant or ongoing support of
92%after180days(Table 1)[14].Theobservedsurvivalrates
were similar to 90% for a control group of commercially-
available devices including not only HeartMate II, but also
patients with pulsatile ﬂow XVE and Thoratec IVADs. The
functional capacity and qualityof life were improved at three
month after placement, as with approved pumps [14]. In
Figure 5 the actuarial survival of the most currently used
second (HeartMate II) and third-generation (HVAD) rotary
blood pumps are highlighted. However, whether the third-
generation of rotary blood pumps will result in signiﬁcant
improvements in clinical outcomes over those observed with
the second-generation of rotary pumps with axial design is
not known at this time.
The currently reported HVAD-related infection rate
ranges from 10.7% (driveline exit) to 6.4% (sepsis). In the
study cohort, no pump pocket infection was seen [14]. The
observed stroke rates were 0.11 events per patient-year for
ischemic and 0.05 for hemorrhagic stroke, respectively [14],
compared to 0.09 and 0.05 in the HeartMate II clinical trial
[7], and 0.05 and 0.01 in the more recent HeartMate II post
approval study [4]. 50% of ischemic strokes in the HVAD
trial occurred within 48 hours following deviceimplantation
[14].
Quality-of-life improvements with LVAD therapy can
be dramatic. In support, we note an early study of the
HeartMate II in the Bridge-to-Transplant context which
showed that 43% of patients improved from NYHA Class
IV (symptomatic at rest: mostly bed-bound) to Class I (no
symptoms and no limitation in ordinary physical activity),
while another 43% improved from Class IV to Class II (mild
symptoms and slight limitation on activity) or Class III
(marked limitations; comfortable only at rest) [10].
While the number of quality of life focused studies
remains somewhat limited, recent data includes presenta-
tions from ACC and ISHLT 2010. For example, one study
examined three quality of life measurements from the6 Cardiology Research and Practice
Table 1: Survival after HVAD Implantation: Evaluation of Heart-
Ware HVAD left ventricular assist device for the treatment of
advanced heart failure: Results of the ADVANCE Bridge to trans-
plant Trial.
ADVANCE Trial Outcomes at 180 days∗
Transplant or alive 92.0%
Alive 62.8%
Transplant 29.2%
Device exchange 4.4%
Death 3.6%
∗Presentation at the AHA meeting 2010 [14].
HeartMate II BTT and DT trial, including the Minnesota
Living withHeart Failure(MLWHF),Kansas CityCardiomy-
opathy Questionnaires (KCCQ) and 6-minute walk distance
(6MWD). The study found signiﬁcant improvements in all
QoL measurements from baseline to 6 months. The presen-
tation also highlighted that even greater improvements are
possible in the Destination Therapy population compared to
BTT patients (39% improvement in DTversus BTT patients,
P = .003), likely due to their generally sicker status [4–6].
Indeed, from the published clinical experience, patients
themselves will ﬁnd quality of life beneﬁts to be a more
attractive justiﬁcation for LVAD implantation than even
improvementsinsurvival. Asaresult,theseobservedbeneﬁts
may provide a signiﬁcant driver for device uptake [4, 5].
3.PatientSelection
One of the most important aspects of device implantation
is patient selection. Heart failure in some form must be
present. Signs of failure such as pulmonary capillary wedge
pressure higher than 20mm Hg, cardiac index less than
2.0L/min/m2, or systolic blood pressure below 80mm Hg
despite best medical management should be present [10].
Columbia University and the Cleveland Clinic Foundation
devised a scoring system in 1995 to predict which patients
would have a successful outcome after LVAD implantation
[41]. However, as the technology evolved, it widened and
extendedtheuseofthesedevicesandtheColumbiascorewas
revised to betterreﬂect thecurrent LVAD-eligiblepopulation
[42]. The previous score utilized 10 factors found to be
signiﬁcantformortalityusingunivariateanalysiswithascore
higher than 5 corresponding to more than a 33% risk of
postimplantation death [41]. The revised score was based
on 130 patients receiving vented electric HeartMate devices
from 1996 to 2001. Univariate and multivariate analyses
were performed to determine operative mortality. The new
preoperative risk factors predicting mortality by univariate
analysis are: previous LVAD/RVAD (right ventricular assist
device),acutemyocardial infarction, postcardiotomy, central
venouspressure (CVP) greaterthan 16mm Hg,prothrombin
time (PT) greater than 16 seconds, preoperative ventilation,
redo-surgery, coronary artery disease, and dilated cardiomy-
opathy. Interestingly, preoperative renal insuﬃciency was
not found to impact survival in the new scoring system,
Table 2: Clinically used adult LVAD types.
First-generation
LVADs
Second-generation
LVADs
Third-generation
LVADs
Pump
design Pulsatile ﬂow Continuous-ﬂow
(axial pump)
Continuous-ﬂow
(centrifugal pump)
LVAD
types
HeartMate XVE
Novacor LVAS
Thoratec LVAD
HeartMate II
Jarvik FlowMaker
Incor Berlin Heart
HeartWare LVAD
DuraHeart LVAS
unlike the old system. This is likely due to aggressive
treatment of renal insuﬃciency with ultraﬁltration and
hemodialysis. A stepwise linear regression model identiﬁed
a ventilated patient and a previous LVAD as independent
predictors of mortality following device insertion [42, 43].
After multivariate analysis the 5 new factors included in the
scoring system were: ventilated patients (score of 4), redo
surgery (score of 2), previous LVAD inserted (score of 2),
CVP higher than 16mm Hg (score of 1), and PT higher than
16 seconds (score of 1). A score higher than 5 corresponds
with a 47% mortality, compared with 9% mortality for a
s c o r el o w e rt h a n5 .T h ep o s i t i v ea n dn e g a t i v ep r e d i c t i v ev a l u e
of this scoring system is 79% and 70%, respectively [42].
The Seattle Heart Failure Model (SHFM) is a prospective
validatedmultivariateriskmodelandatoolthatpredictssur-
vival ofheart failurepatient[44,45].Thisscoremay facilitate
identiﬁcations of high-risk patients to evaluate for potential
LVAD therapy, by providing an estimate of 1- to 5-year
outcome with medical therapy [43]. The SHFM, with the
addition of inotropic use, mechanical support (intraaortic
ballon pump), and ventilation, is able to successfully provide
risk stratiﬁcation in patients considered for potential LVAD
therapy [43].
The study by Holman et al. identiﬁed preoperative risk
factors for mortality based on the results of INTERMACS
registry (registry of FDA approved durable mechanical
circulatory assist device). In this analysis older age (relative
risk = 1.41; P<. 001), ascites (relative risk = 2.04; P = .003),
increased bilirubin (relative risk = 1.49; P<. 05),and cardio-
genic shock (INTERMACS level 1) (relative risk = 1.59; P =
.02) are highly associated with postimplant mortality [28].
The urgency of device placement has also been shown
to play a factor in survival. In a study by Deng et al.
patients receiving emergent LVADs had a lower survival to
transplantation rate than those receiving devices urgently or
those who did not need devices [46]. However, electively
implanted LVAD patients with no subsequent transplanta-
tion had better survival than medically treated heart failure
patients who also did not get transplanted. This occurred
despite the fact that the LVAD recipients were a sicker group
of patients [46].
4.Summary
The shortage ofappropriatedonororgans andtheexpanding
pool of patients waiting for heart transplantation have led
to growing interest in alternative strategies, particularly inCardiology Research and Practice 7
Table 3: Most commonlyused LVADs.
LVAD Types HeartWare System HeartMate II
Support duration
(patient years) 47.8 [20] 211 [5]
Outcome
(i) 30 days survival 98% [14] 96% [39]
(ii) 1-year survival 91% [14] 85% [39]
(iii) 2-year survival — 70% [4]
Quality of life +++ [14] +++ [5, 10]
Approval
(i) BTT Yes Yes
(ii) DT No, but on the way Yes
Advantages
(i) Miniaturized
pump
(i) Long-term
support
(ii) Implanted in
the intrapericardial
space
(ii)
Destination
therapy
(iii) Indicated to
support patients
with BSA ≥ 1.2m2
(iii)
Durability
(iv) Right
ventricular
implantation
(iv) More
than 1500
implants in
Europe
(v) Biventricular
implantation
Disadvantages
(i) Driveline (i) Require a
pump pocket
(a) Infection (ii) Driveline
(b) Breaking (a)
Infection
(ii) Neurological
dysfunction
(b)
Breaking
(iii) Hemolysis
(iii)
Neurological
dysfunction
(iv) Bleedings
BTT: bridge to transplant; DT: destination therapy; BSA: body surface area.
mechanical circulatory support. The spectrum of VAD ther-
apy is clearly expanding. The second and third-generation of
nonpulsatile continuous-ﬂow ventricular assist devices have
yielded encouraging preliminary data suggesting improved
outcomes, quality of life, and device durability. Table 2
shows the typical classiﬁcation of adult LVADs and Table 3
highlights the outcome, complications and characteristics
of the most commonly used LVADs. The development of
validated risk stratiﬁcation models will lead to improved
patient selection and timing of device implant, with over-
all improved outcomes over time. However, clinical trials
are needed to demonstrate the potential and superiority
of these promising therapies. Further minimally invasive
surgical implantation techniques in combination with newer
miniaturized pumpsmayreducetheoperativerisk,especially
in the elderly. The development of fully implantable LVAD
technology that incorporates an implantable battery with
transcutaneous energy transfer (TET) may also lead to
reduced infection rate (infection reduction technology).
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